Clal Biotechnology Industries Ltd

As of June 30, 2023, Clal Biotechnology Industries Ltd carries a market capitalization of 8.08B, placing it among publicly traded companies globally. Its enterprise value stands at 9.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2023, Clal Biotechnology Industries Ltd has 156.85M shares outstanding.

These figures are as of June 30, 2023.

As of June 30, 2023, Clal Biotechnology Industries Ltd maintains a current ratio of 3.61, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2023.

Over the twelve months ended June 30, 2023, Clal Biotechnology Industries Ltd recorded 1.20M in income tax expense.

As of the close on October 22, 2026, Clal Biotechnology Industries Ltd's stock has declined approximately 30.72% over the past 52 weeks. The 50-day moving average sits at 23.86, while the 200-day moving average is 28.48.

As of June 30, 2023, Clal Biotechnology Industries Ltd holds 1.05B in cash and equivalents against 668.60M in total debt, resulting in a net debt position of -1.05B. Total book value stands at 13.41B, with working capital of 979.90M providing operational flexibility.

These figures cover the twelve months ended June 30, 2023.

Clal Biotechnology Industries Ltd's most recent stock split took place on April 22, 2013 with a 798:821 split ratio.